PLSE - Pulse Biosciences, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Pulse Biosciences, Inc.

3957 Point Eden Way
Hayward, CA 94545
United States
510-606-4600
http://www.pulsebiosciences.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees54

Key Executives

NameTitlePayExercisedYear Born
Mr. Darrin R. UeckerPres, CEO & Director569.44kN/A1966
Mr. Brian B. DowCFO, Sr. VP of Fin. & Admin., Treasurer and Sec.381.39kN/A1969
Mr. Edward A. EbbersExec. VP & GM of Dermatology303.13kN/A1960
Dr. Richard Nuccitelli Ph.D.Chief Science OfficerN/AN/AN/A
Dr. Holly Hartman Ph.D., J.D.VP of Bus. Devel. & Corp. StrategyN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pulse Biosciences, Inc. operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.

Corporate Governance

Pulse Biosciences, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.